SHP15 Mar 2012 11:02
Shire to acquire FerroKin BioSciences, Inc., and its Phase 2 iron chelator
treatment
Dublin, Ireland - March 15, 2012 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the
global specialty biopharmaceutical company, announces that it has signed an
agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100
million, payable in cash at closing, plus potential post-closing milestone
payments of up to $225 million, depending upon the achievement of certain
clinical development, regulatory and net sales targets.
* A strategic step in building Shire's hematology business (which already
includes Xagrid and a growing development pipeline)
* Adds a differentiated product in development (iron chelator FBS0701), with
global rights, in a global market currently worth over $900 million and
growing(1)
* Serves chronic patient need for treatment of iron overload following
numerous blood transfusions. Excess iron in vital organs such as the liver
and heart increases the risk of organ failure and is the principal cause of
death in transfusion-dependent patients(2)
* Consistent with Shire strategy of developing and commercializing
differentiated specialist products prescribed by specialist physicians
(hematologists/ hematologist-oncologists) served by a small sales force
* FBS0701 will be developed to demonstrate clinical efficacy and an
attractive safety profile relative to currently approved chelating agents:
* Global filing planned for indications for Myelodysplastic Syndrome and
hemoglobinopathies initially
* Phase 2 studies underway with additional trials planned
* Potential launch as early as 2016